In 2019, Wang et al. designed, synthesized and evaluated a new series of VCP/p97 pyrimidine inhibitors and identified that the compound N-(1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl −1H-indol-4-yl)methanesulfonamide exerted a good antiproliferative effect on non-small cell lung cancer cells (A459) and showed good liver stability in mice, dogs and humans [148]. The gene discussed is VCP; the disease is non-small cell lung carcinoma.